- Home
- BYSI vs YI Comparison
BYSI vs YI Comparison
Compare BYSI & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- YI
- Stock Information
- Founded
- BYSI 2010
- YI 2010
- Country
- BYSI United States
- YI China
- Employees
- BYSI N/A
- YI N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- BYSI Health Care
- YI Consumer Staples
- Exchange
- BYSI Nasdaq
- YI Nasdaq
- Market Cap
- BYSI 73.4M
- YI 60.7M
- IPO Year
- BYSI 2017
- YI N/A
- Fundamental
- Price
- BYSI $1.79
- YI $4.45
- Analyst Decision
- BYSI
- YI
- Analyst Count
- BYSI 0
- YI 0
- Target Price
- BYSI N/A
- YI N/A
- AVG Volume (30 Days)
- BYSI 35.0K
- YI 29.4K
- Earning Date
- BYSI 11-11-2025
- YI 11-26-2025
- Dividend Yield
- BYSI N/A
- YI N/A
- EPS Growth
- BYSI N/A
- YI N/A
- EPS
- BYSI N/A
- YI N/A
- Revenue
- BYSI N/A
- YI $1,979,883,442.00
- Revenue This Year
- BYSI N/A
- YI N/A
- Revenue Next Year
- BYSI N/A
- YI N/A
- P/E Ratio
- BYSI N/A
- YI N/A
- Revenue Growth
- BYSI N/A
- YI N/A
- 52 Week Low
- BYSI $0.98
- YI $4.15
- 52 Week High
- BYSI $3.44
- YI $11.35
- Technical
- Relative Strength Index (RSI)
- BYSI 49.29
- YI 31.35
- Support Level
- BYSI $1.72
- YI $4.48
- Resistance Level
- BYSI $1.86
- YI $4.97
- Average True Range (ATR)
- BYSI 0.07
- YI 0.22
- MACD
- BYSI 0.01
- YI 0.06
- Stochastic Oscillator
- BYSI 68.52
- YI 8.94
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.